Range Low Price High Price Comment
30 days $1.54 $3.16 Monday, 29th Apr 2024 GLYC stock ended at $1.55. This is 5.49% less than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 12.34% from a day low at $1.54 to a day high of $1.73.
90 days $1.54 $3.47
52 weeks $1.11 $3.53

Historical GlycoMimetics prices

Date Open High Low Close Volume
Feb 01, 2016 $4.65 $4.70 $4.50 $4.66 12 500
Jan 29, 2016 $5.13 $5.22 $4.65 $4.71 40 700
Jan 28, 2016 $5.23 $5.33 $5.02 $5.04 13 700
Jan 27, 2016 $4.78 $5.05 $4.68 $5.01 31 200
Jan 26, 2016 $5.18 $5.24 $4.74 $4.81 8 100
Jan 25, 2016 $5.04 $5.30 $5.04 $5.17 6 800
Jan 22, 2016 $5.17 $5.29 $4.94 $5.05 6 300
Jan 21, 2016 $5.09 $5.18 $5.09 $5.14 9 500
Jan 20, 2016 $4.54 $5.05 $4.50 $4.82 8 700
Jan 19, 2016 $4.64 $4.87 $4.50 $4.61 32 400
Jan 15, 2016 $4.67 $4.78 $4.23 $4.27 30 200
Jan 14, 2016 $4.50 $4.89 $4.31 $4.77 25 000
Jan 13, 2016 $5.08 $5.11 $4.53 $4.53 45 500
Jan 12, 2016 $5.19 $5.36 $4.96 $4.96 27 100
Jan 11, 2016 $5.34 $5.34 $4.95 $5.01 13 100
Jan 08, 2016 $5.62 $5.62 $5.18 $5.19 9 100
Jan 07, 2016 $5.39 $5.48 $5.18 $5.22 23 900
Jan 06, 2016 $5.68 $5.97 $5.46 $5.48 21 700
Jan 05, 2016 $6.03 $6.03 $5.76 $5.81 27 900
Click to get the best stock tips daily for free!

About GlycoMimetics

GlycoMimetics GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing G... GLYC Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT